Grand Rounds, Inc.

grandrounds.com

Grand Rounds’ vision is to create a path to great health and health care, for everyone, everywhere. Founded in 2011, the company provides an employer-based technology solution that connects members and their families to high-quality care. With Grand Rounds, employers get a personalized, high-performance network at scale, while their employees get the tools and support needed to navigate their care on their own terms. Named Rock Health’s 2018 Fastest Growing Company and second among Glassdoor’s 2016 Best Places to Work, Grand Rounds helps restore individual health and quality of life, and offers employers lower health care spend and higher employee productivity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

OCEAN GENOMICS AND GENINUS TEAM UP TO DEVELOP RNA-BASED BIOMARKERS AND ADVANCE RESEARCH.

Ocean Genomics, Geninus Inc | March 30, 2021

news image

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers. The two organizations will dispatch in Korea Ocean Genomics' high level AI-based t...

Read More

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

news image

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More

THERMO FISHER SCIENTIFIC HIGHLIGHTS GROWING CAPACITY FOR BIOLOGICS, CELL AND GENE THERAPY PRODUCTION DURING BIO 2020

PR Newswire | June 08, 2020

news image

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the BIO International Convention, June 8-12, now a virtual event at www.bio.org/events/bio-digital."We can now provide an uninterrupted path from development to commercialization for biopharma companies, small to large, in geographies worldwide and across vaccine...

Read More

CELL AND GENE THERAPY

ISOPLEXIS ACQUIRED A LARGE PORTFOLIO OF DNA AND RNA SEQUENCING TO ENABLE INTEGRATED SINGLE-CELL SEQUENCING AND PROTEOMIC SOLUTIONS

IsoPlexis | May 26, 2021

news image

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadma...

Read More
news image

CELL AND GENE THERAPY

OCEAN GENOMICS AND GENINUS TEAM UP TO DEVELOP RNA-BASED BIOMARKERS AND ADVANCE RESEARCH.

Ocean Genomics, Geninus Inc | March 30, 2021

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers. The two organizations will dispatch in Korea Ocean Genomics' high level AI-based t...

Read More
news image

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More
news image

THERMO FISHER SCIENTIFIC HIGHLIGHTS GROWING CAPACITY FOR BIOLOGICS, CELL AND GENE THERAPY PRODUCTION DURING BIO 2020

PR Newswire | June 08, 2020

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the BIO International Convention, June 8-12, now a virtual event at www.bio.org/events/bio-digital."We can now provide an uninterrupted path from development to commercialization for biopharma companies, small to large, in geographies worldwide and across vaccine...

Read More
news image

CELL AND GENE THERAPY

ISOPLEXIS ACQUIRED A LARGE PORTFOLIO OF DNA AND RNA SEQUENCING TO ENABLE INTEGRATED SINGLE-CELL SEQUENCING AND PROTEOMIC SOLUTIONS

IsoPlexis | May 26, 2021

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadma...

Read More